(Q44889298)

English

Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

author name string

Qigui Yu

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Brad Jones

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Ningjie Hu

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Hong Chang

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sidrah Ahmad

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Jun Liu

6

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Mark Parrington

7

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Mario Ostrowski

8

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

language of work or name

0 references

publication date

30 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

40-41

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

6376-6391

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Vaccinia and other poxvirus expression vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Roles of vaccinia virus in the development of new vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Vaccinia virus expression vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Viruses as vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Poxvirus tropism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Smallpox vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV inf

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

NYVAC: a highly attenuated strain of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Highly attenuated poxvirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Susceptibility of different leukocyte cell types to Vaccinia virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

The role of CD4+ T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected indivi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Regulation of Toll-like receptor (TLR)2 and TLR4 on CD14dimCD16+ monocytes in response to sepsis-related antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Safety profile of recombinant canarypox HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Role of therapeutic vaccines in the control of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Mobilization of human lymphoid progenitors after treatment with granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.06.011

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44889298&oldid=2055821506"